Slingshot members are tracking this event:

Phase 3 data of ALCANZA trial of ADCETRIS for relapsed CD30-positive cutaneous T-cell lymphoma due 2H 2016

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
SGEN Community voting in process

Additional Information

Management Comment
“We are pleased to announce the completion of patient enrollment in the phase 3 ALCANZA clinical trial evaluating ADCETRIS as a potential treatment for CD30-expressing CTCL,” said Clay Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. “We look forward to reporting results from the ALCANZA trial in the second half of 2016 to potentially support an ADCETRIS supplemental Biologics License Application seeking a label expansion for use in this setting.”
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 01, 2016
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3 Data, Alcanza Trial, Adcetris, Relapsed, Cd30-positive Cutaneous T-cell Lymphoma